Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
October 11, 2016 08:00 ET
|
Exicure, Inc.
SKOKIE, Ill., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced results...
Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
April 26, 2016 07:00 ET
|
Exicure, Inc.
SKOKIE, Ill., April 26, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced the dosing...
Exicure Co-Founder Awarded Prestigious Dan David Prize
February 12, 2016 11:57 ET
|
Exicure, Inc.
SKOKIE, Ill., Feb. 12, 2016 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David...
Exicure Co-Founder Awarded Inaugural Sackler Prize
October 15, 2015 06:00 ET
|
Exicure, Inc.
SKOKIE, Ill., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the inaugural recipient of the Raymond and...
AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform
April 22, 2015 16:01 ET
|
Exicure, Inc.
SKOKIE, Ill., April 22, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...
AuraSense Therapeutics Adds to Series C Financing
February 04, 2015 10:36 ET
|
Exicure, Inc.
SKOKIE, Ill., Feb. 4, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...
AuraSense Therapeutics Welcomes Key Personnel, Further Expanding Leadership Team
October 01, 2014 09:45 ET
|
Exicure, Inc.
SKOKIE, Ill., Oct. 1, 2014 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...